echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The price of Chinese listed pharmaceutical companies is revealed! The market value of three enterprises has exceeded 100 billion

    The price of Chinese listed pharmaceutical companies is revealed! The market value of three enterprises has exceeded 100 billion

    • Last Update: 2019-04-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] recently, wind released the list of "top 500 listed companies in China by market value" According to statistics, there are 43 pharmaceutical companies on the list Among them, the market value of Hengrui pharmaceutical, Mindray medical and Wuxi Pharmaceutical Co., Ltd has exceeded 100 billion yuan Hengrui pharmaceutical announced its 2018 annual report on the evening of February 15, 2019 According to the annual report, in 2018, Hengrui pharmaceutical's revenue reached 17.418 billion yuan, a year-on-year increase of 25.89% The net profit attributable to shareholders of the listed company was 4.066 billion yuan, a year-on-year increase of 26.39% The net profit attributable to shareholders of the company after deducting non recurring profit and loss was 3.803 billion yuan, a year-on-year increase of 22.60% According to the analysis of the annual report, there are two main driving factors for Hengrui's performance growth in 2018: first, the harvest of innovation achievements; second, the optimization of product structure Specifically, in terms of innovation achievements, as of the date of the annual report, Hengrui pharmaceutical has approved the listing of four innovative drugs, including iricoxib, apatinib, thiopefigeristine injection and pyrrolidine Among them, the drugs approved for production in 2018 are thiopefigeristine injection and pyrrolidine In terms of product structure optimization, in 2018, Hengrui pharmaceutical continued to optimize its product composition In addition to tumor drugs, non anti-tumor drugs represented by surgical anesthesia, contrast agents and characteristic infusion gradually expanded the market in their respective treatment fields and maintained a stable growth trend According to the annual report, in the future, Hengrui pharmaceutical will continue to promote R & D innovation and internationalization of pharmaceutical products, while focusing on the optimization and upgrading of product structure to ensure the sustainable growth of the company's performance On February 27, Meirui medical released the 2018 annual performance report In 2018, the company achieved a total operating revenue of about 13.753 billion yuan, an increase of 23.09% year on year; an operating profit of 4.278 billion yuan, an increase of 48.57% year on year; a total profit of 4.238 billion yuan, an increase of 44.59% year on year; and a net profit of 3.719 billion yuan, an increase of 43.65% year on year attributable to the shareholders of the company in Shanghai The main reason for the significant increase in performance is that during the reporting period, the company's main business continued to show a good development trend, and the product competitiveness continued to strengthen, and the sales in the product structure steadily improved In addition, centering on the direction of strategic development planning, the company has steadily and orderly promoted various work, actively exerted its advantages in R & D, technology, procurement, manufacturing, quality, product, market, channel, service and other aspects, integrated business resources, continuously increased its market expansion, and achieved healthy and stable growth in product sales and revenue At the same time, the company's management strengthens the continuous improvement of operating efficiency, so the net profit is higher than the growth of operating income, and the net interest rate is significantly improved On March 22, Wuxi apptec today released its 2018 annual report The company's operating revenue was 9.614 billion yuan, an increase of 23.8% year on year Based on the average exchange rate of the same period last year, the operating revenue was 9.739 billion yuan, an increase of 25.4% year on year The net profit attributable to shareholders of the listed company was 2.261 billion yuan, an increase of 84.2% year on year According to the annual report, in 2018, through 27 operating bases and branches around the world, Wuxi apptec provided services to more than 3500 customers from more than 30 countries around the world, including 1400 new customers in 2018 The main reasons for the growth are: on the one hand, the company helps customers around the world to promote the research and development process of major pharmaceutical products, many new drugs have obtained FDA breakthrough therapy, orphan drug qualification, and FDA "express channel" and other recognition On the other hand, the company continues to deepen and strengthen cooperation with domestic customers to empower the domestic small molecule new drug research and development industry The company provides integrated new drug discovery and R & D services for domestic customers from the drug discovery stage until the ind application is submitted to the State Food and drug administration.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.